FDA Approves Rasonque for Pancreatic Cancer

The first RAS inhibitor cleared for pancreatic cancer targets a gene family driving most cases of the disease.

Updated on Nov. 7, 2026 in Cancer

FDA Approves Rasonque for Pancreatic Cancer

In August 2026, the FDA approved Rasonque, generically known as daraxonrasib, for pancreatic cancer patients. The approval covers only second-line patients who have not responded to a previous treatment.

Why it matters

Mutations in the RAS family of genes drive over 90% of pancreatic cancer, so a drug aimed directly at that pathway opens a new option where few have existed. The approval follows positive results from large clinical trials, including one at the Karmanos Cancer Institute in Detroit.

Mutations in the RAS family of genes drive over 90% of pancreatic cancer, the basis for targeting this pathway. The drug carries an annual pre-insurance cost of $480,000, and the source does not detail the trial outcome figures behind the approval.

The players

Revolution Medicines

The California-based drugmaker that manufactures Rasonque, a company focused on developing therapies that target RAS-driven cancers.

Pancreatic Cancer Action Network

An Iowa-headquartered advocacy organization that supports pancreatic cancer patients, research, and awareness efforts nationwide.

The details

Rasonque specifically targets mutations in the RAS family of genes, which control cell division and growth, and is prescribed to adults who have not responded to previous treatment. It is the first RAS inhibitor approved for pancreatic cancer.

August 2026: the FDA approved Rasonque for pancreatic cancer patients.

Big Picture

Rasonque is the first RAS inhibitor approved for pancreatic cancer, extending a targeted-therapy approach built around the RAS gene family. Because RAS mutations drive over 90% of these tumors, the approval places a pathway-specific drug where treatment options have historically been limited.

For adults with pancreatic cancer who have not responded to a previous treatment, Rasonque is now an FDA-approved option. The annual pre-insurance cost of $480,000 means coverage and out-of-pocket exposure will be a central consideration for patients and families.

The takeaway

Targeted therapies aimed at specific genetic drivers are reshaping cancers once treated with broadly applied chemotherapy. Patients considering new options should discuss eligibility, including prior-treatment history, with their oncologist.